Pierrel S.p.A.: Finalized The Acquisition Of The US Activities Of Encorium Inc.

Pierrel S.p.A., provider of research, development (Contract Research) and manufacturing (Contract Manufacturing) of drugs for third parties, has finalised today the acquisition of Encorium USA, line of business of the American group Encorium Group Inc., by Pierrel Research USA Inc., the NewCo owned 100% by Pierrel S.p.A..

Pierrel Research USA Inc., based in Philadelphia (PA), will be headed by Dr. David Ginsberg as CEO and by Dr. Giorgio Mosconi, as Chief Strategy & Operations Development.

The Eng. Dr. Canio Giovanni Mazzaro will be the Chairman.

Pierrel S.p.A.

Pierrel S.p.A., provider to the pharmaceutical industry and specialized in Research and development (Contract Research) and production (Contract Manufacturing) of drug products, is quoted on the Italian Stock Exchange market. The Pierrel Group has more than 50 years experience in the pharmaceutical sector and is one of the main European manufacturers of dental anaesthetic drug products. The Group operates mainly in the ‘outsourcing sector', providing services to the pharmaceutical companies in two areas: ‘Contract Manufacturing' of drug products and consultancies and services for research and development of new molecules and drug products, ‘Contract Research'. Pierrel S.p.A., with Head Quarters in Milan and manufacturing plant in Capua (CE) is a reference partner of the main Pharmaceutical Companies. Pierrel controls the Swiss Company ‘ Pharmapart AG', the German Company ‘IFE Europe Gmbh', the Hungarian Company ‘Goodwill Research kft' and the Italian Company ‘Hyperphar Group S.p.A.'; All specialized in consultancy services in medical and clinical research, scientific services for the development and execution of clinical trials, registration and licensing of medicinal drug products and medical devices and regulatory and marketing consultancy.

SOURCE: Pierrel S.p.A.